Abstract: The U.S. Primary aldosteronism: an Endocrine Society clinical practice guideline updated recommendations for diagnosing and managing primary aldosteronism (PA), emphasizing early and comprehensive screening. This approach aligns with the hypertension specialty concept that "every hypertensive patient should have the cause of their hypertension identified." This article evaluates the guideline's innovativeness, scientific rigor, and practicality. Additionally, it considers the current state of hypertension prevention and treatment in China, offering preliminary reflections: the importance of comprehensive screening to ensure timely diagnosis and treatment, the need for quantitative diagnostic criteria to enhance care standards, and the necessity of adhering to indications for precise treatment control. These principles and measures aim to improve the early detection and effective management of PA, ultimately safeguarding patient health.